Shenzhen Tuowei Anchuang Technology Development

Turier Biotech (Shenzhen Tuwei Anchuang Technology Development Co., Ltd.) is a clinical-stage biopharmaceutical company based in Shenzhen, China, specializing in the development of innovative polypeptide (peptide) drugs. Founded in 2016, the company focuses on therapeutic areas including organ fibrosis (liver and lung), inflammation, immunity, and metabolic diseases. Its lead candidate, TB-001, is a dual GLP-1R/GCGR agonist currently in Phase 2 clinical trials for liver cirrhosis and chronic hepatitis B. Turier Biotech leverages its proprietary synthetic peptide platform to create a diverse pipeline of long-acting and multi-target therapies, including TB-B002D for idiopathic pulmonary fibrosis and TB-D004C for diabetic kidney disease.